Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high3.6750 05/12/16
52 week low1.5500 18/09/17
52 week change -0.7500 (-31.58%)
4 week volume26,846,073 26/09/17

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

PDMR Interest in Shares and Share Options

RNS Number: 3426T ReNeuron Group plc 11 October 2017 11 October 2017 AIM: RENE ReNeuron Group plc Director/PDMR Interest in Shares and Share Options ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that, on 9 October 2017 , the following grants made on 11 Septe...

Presentation of positive pre-clinical data

RNS Number: 0080T ReNeuron Group plc 09 October 2017 AIM: RENE 9 October 2017 ReNeuron Group plc ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference Data show that ExoPr0 can inhibit proliferation in a diverse panel of cancer cell lines ReNeuron Group plc (the "Company") (AIM:...

Directors' Interest in Shares and Share Options

RNS Number: 4642Q ReNeuron Group plc 12 September 2017 12 September 2017 AIM: RENE ReNeuron Group plc Directors' Interest in Shares and Share Options ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that on 11 September 2017 , the following awards were made u...

Result of AGM

RNS Number: 9753P ReNeuron Group plc 06 September 2017 6 September 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Result of AGM ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting, held earlier to...

AGM Trading Update

RNS Number: 9398P ReNeuron Group plc 06 September 2017 6 September 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") AGM Trading Update ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, i s pleased to provide a trading update ahead of today's Annual General Meeting. We are...

Non-executive Director Appointment

RNS Number: 5221P ReNeuron Group plc 01 September 2017 1 September 2017 AIM: RENE ReNeuron Group plc Non-executive Director Appointment ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the appointment of Dr Claudia D'Augusta as a Non-executive Direc...

Block Listing Review and TVR

RNS Number: 5069P ReNeuron Group plc 01 September 2017 01 September 2017 AIM: RENE ReNeuron Group plc Block Listing Review and Total Voting Rights ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rule...

Neil Woodford 'very confident' he can deliver 10%-plus yearly returns

Woodford Patient Capital's performance has picked up over the last three months and Neil Woodford is optimistic. Marina...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Latest discussion posts More

  • Snippet for info.....

    I believe that Professor Karol Sikora is an advisor to Reneuron on the potential of exosome based oncology treatments. Here he gives his view on the NHS it's issues and his ...
    21-Oct-2017
    fredd1eboy
  • Re: bit of info

    oops dropped the s in https as well as the : on occasion in links - lol apologies nevermind enough there for anyone to follow gist mol
    20-Oct-2017
    mol42
  • bit of info

    fwiw thought i'd post tonight - abeit found a while ...
    20-Oct-2017
    mol42

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.18%
BP12%
BARCLAYS11%
ROCKHOPPER11%
ROYAL BANK SCOT11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE